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. After transplantation, 30-50% of these patients develop a recurrence of their initial disease, leading to roughly 50% of graft lost 3, 4 . In 90% of these patients, nephrotic syndrome recurs within the first hours after transplantation, suggesting the intervention of a circulating albuminuric factor. The beneficial effect of plasmapheresis also supports this hypothesis [3] [4] [5] [6] . Several attempts have been made in order to determine the nature of this putative albuminuric factor, but its molecular characterization has remained elusive. We recently showed that the Buffalo/Mna rat strain spontaneously develop a nephrotic syndrome with a histological pattern closely similar to the human disease 7 .
Moreover, we demonstrated the recurrence of proteinuria in Buffalo/Mna recipients of a normal rat kidney whereas nephrotic Buffalo/Mna kidneys recovered albuminuric permselectivity after transplantation in a normal recipient, suggesting the presence of extra renal factor(s) and making this strain the first possible relevant model of the human disease 8 .
The recent observation of an association between INS relapse and an atypical Th2 polarization, characterized by c-maf activation and IL-4 down regulation 9 , raises the question of implication of T cells in the pathophysiology of this disease. In this work, we have investigated the role of a putative soluble factor, sST2, whose promoter contains the c-maf recognition element (MARE) (DS, unpublished), as a candidate in the narrow but much selected population of INS recurrent patients after transplantation. In human, the ST2 gene encodes for two main products by alternative splicing: a transmembrane protein called ST2L, which is composed of an extracellular region with three immunoglobulin domains and of an intracellular toll-interleukin-1 receptor (TIR) domain, and a soluble secreted protein, sST2, which only includes the extracellular part of ST2L. The soluble form is secreted by activated Th2 cells which express ST2L at their surface 10 . In mice models, the ST2 protein has been described as a stable marker of a subset of activated Th2 cells independent of the production of IL-4, IL-5 and IL-10
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, although it is not an universal marker of this T cell phenotype. 
RESULTS

High sST2 levels are associated with INS recurrence after renal transplantation:
sST2 serum concentrations were measured before and after renal transplantation in three clinical situations: 1/ patients with INS recurrence, 2/ patients with INS non-recurrence and 3/ patients with non-INS disease on native kidneys and who displayed high proteinuria levels from different origins after transplantation. The clinical characteristics of these patients are summarized in Table 1 . We did not detect significant differences in serum sST2
concentrations between these three cohorts before transplantation ( Figure 1 ). In contrast, sST2 levels were strongly increased in recurrent patients after transplantation (median = 617.5 pg/mL vs. 124 pg/mL before transplantation, P < 0.01), while they remained low in the comparison in the non-recurrent group (median = 23 pg/mL, P < 0.001) and in the group of patients without INS (median = 158.5 pg/mL, P < 0.01).
Determination of the capacity of sST2 concentrations to distinguish INS recurrence and INS non-recurrence by ROC curve analysis ( Figure 2A ) revealed an excellent discriminative power (AUC = 0.9, 95% confidence interval 79% -99%), with a sensitivity of 80% and a specificity of 97% at a cut-off value of 205 pg/mL of circulating sST2. The ROC curve analysis was then applied to compare patients with INS recurrence and patients with non-INS glomerular diseases, who both displayed similar proteinuria levels after transplantation. As shown in figure 2B , sST2 levels also discriminated these two cohorts (AUC = 0.75, 95% confidence interval 59% -89%), with a sensitivity of 55% and a specificity of 86% at a cut-off value of 602 pg/mL of serum sST2.
Altogether, these results point out that post-transplantation recurrence is tightly associated with an upregulation of sST2 in patients with INS, and that measurement of sST2 levels in proteinuric patients after transplantation could discriminate recurrent patients from the others. Moreover, these observations raise the question of a potential involvement of the sST2 protein in the development of this disease.
Recipients with recurrent INS do not accumulate a specific sST2 isoform:
The possibility of an abnormal sST2 isoform was suggested by the absence of proteinuria in some patients with high sST2 levels (allergic diseases). sST2 immunopurified from the plasma of a patient with INS recurrence and a high sST2 level was analyzed by bidimensional electrophoresis (Figure 3 ). Several clusters of spots were detected, but only three of them had a degree of intensity allowing the analysis. The cluster #1 presented the same characteristics as those described for sST2 of the "normal" human serum, i.e. a molecular weight of 57 kDa and an isoelectric point of 8.40 (as described in the SwissProtExpasy database). The two other clusters had only one feature closed to the normal sST2 protein: the isoelectric point for the cluster #2 (approximately 8.00), and the molecular weight for the cluster #3 (about 60 kDa). These three clusters were therefore analyzed by mass spectrometry (LC-ESI-MS/MS). Upon sequencing, the sST2 protein was detected only in the cluster #1 (Table 2) , presenting all the expected characteristics and electrophoretic behavior, suggesting that recurrent patients display the normal isoform of the sST2 protein.
Sera from patients with INS recurrence but not sST2 induce podocyte cell line injury in
vitro:
An immortalized mouse podocyte cell line 16 was used to investigate whether the serum and purified sST2 of recurrent patients could alter morphological and/or functional characteristics of podocytes. Incubation of these cells with serum or plasma from recurrence induced cell body contraction, nucleus retraction and loss of cell processes ( Figure 4 ), whereas the cell morphology was well conserved in podocytes exposed to serum from nonrecurrence, confirming a previous report 17 . However, we found these modifications with only 70% of the sera from recurrence tested, which may point out a limit in the sensitivity of this test. In contrast, we found no podocyte injury after incubation with sera from patients without recurrence. Analysis by dual-labelling immunofluorescence of the cell distribution of F-actin and vinculin showed some major architectural modifications of podocytes incubated with reactive sera from recurrent patients. Indeed, incubated podocytes exhibited a considerable redistribution of actin filaments around the nucleus, with a rarefaction of cortical actin and a scarce expression of vinculin ( Figure 4B ). In contrast, podocytes incubated with serum from patients with non-recurrence displayed a normal phenotype. Altogether, these results support the concept that serum and plasma of INS recurrent patients contain factor(s) capable to directly induce podocytes morphological damages.
In order to determine whether the sST2 protein was implicated in the podocyte injuries we observed in vitro, we purified sST2 from reactive plasmas and tested the activity of the different fractions (initial plasma, plasma sST2-depleted and purified sST2 protein) on differentiated podocytes. We found that podocytes exposed to sST2-depleted plasma exhibited the same architectural modifications than podocytes incubated with the primitive plasma ( Figure 5 ). Furthermore, podocytes exposed to sST2 proteins purified from the same samples displayed a normal phenotype, showing that sST2 is not the serum toxic fraction in recurrent patients.
Achieving high sST2 circulating levels does not trigger proteinuria in rat:
Because the absence of in vitro effect of sST2 on the mouse podocyte cell line does not necessarily exclude a role for sST2 in INS recurrence, we also investigated whether this protein could induce proteinuria and glomerular damages in rat. To do so, we used two experimental approaches. First, we treated Sprague-Dawley rats with an adeno-associated virus coding for the human sST2 protein. Administration of this AAV intravenously did not induce proteinuria in these rats ( Figure 6B ), despite induction of high circulating sST2 levels ( Figure 6A ). Second, we injected directly into the renalry of healthy Lewis 1W rat the totality of sST2 purified from the blood of another Lewis 1W rat or of a nephrotic Buffalo/Mna rat in order to focus as much as possible the potential effects of this protein on the kidney. Figure 7 shows that the increase in blood concentration of sST2 was not associated with an increase in urinary protein. This was the case both for injection of sST2 purified from Lewis 1W rats or from Buffalo/Mna rats.
Altogether, these results do not suggest that sST2 acts directly on the kidney to induce the development of INS recurrence after transplantation.
DISCUSSION
Idiopathic Nephrotic Syndrome is a heterogeneous disease. In non genetic forms, the primary disorder seems to involve the immune system. To date, little is known about immune mechanisms which ultimately lead to the disorganisation of the glomerular filtration barrier and since the first report of INS recurrence following renal transplantation, the pathophysiology of this disease has become a challenge for nephrologists 18 . It has been postulated for a long time that INS results from a T cell dysfunction, leading to the release of a circulating factor responsible for glomerular damages 19 . In this regard, INS patients with recurrence after transplantation represent an interesting "model" in which an immune origin is highly suggested. Over the past 30 years, several teams, including ours, attempted without success to identify a circulating factor in INS. On the basis of an active serum component binding to protein A affinity columns, we have suggested that the permeability factor displays some immunoglobulin-like properties 6 . These findings were also supported by Savin's team which also suggested that a circulating factor with an apparent molecular weight around 50 kDa 5 binds to protein A. We first stated the hypothesis that the sST2 protein could be the factor, whose identity had been approached in these works, since it contains three Ig-like domains, binds with high affinity to protein A and displays a molecular weight of 57 kDa. In addition, a role for sST2 in INS recurrence was also suggested in a study using a subtractive . Despite the fact that sST2 was not found increased in this previous study, this observation enables an interesting connexion with the ST2 protein, whose gene promoter contains the c-maf recognition element (MARE) (DS, unpublished). Moreover, several studies pointed out the ST2 protein as a selective marker of Th2 cells [10] [11] [20] [21] , which correlates with the atypical Th2 polarization described in INS [22] [23] [24] . Finally, sST2 seems to be tightly associated with allergic airways inflammation [12] [13] [14] , which have also been associated with some cases of nephrotic syndrome [25] [26] [27] .
In this study, we reported that the sST2 production is strongly increased after detected no difference between the tested groups before transplantation, precluding relevance of sST2 levels measurement as a predictability test for INS recurrence.
Since increased production of sST2 appears associated with INS recurrence, we tested the hypothesis that this protein could be a permeability factor related to the development of INS. However, since sST2 is also increased in the sera of patients in acute pathological conditions such as myocardial infarction, sepsis, trauma or exacerbation of idiopathic pulmonary fibrosis [28] [29] [30] , all clinical situations not associated with proteinuria, the possibility of the existence of an abnormal sST2 isoform in recurrent INS patients was studied in a caricatural recurrent patient with a high circulating sST2 level. The bidimensional analysis of the sST2 protein purified from the plasma of this patient revealed the same isoform as described in healthy individuals.
To further explore a putative role of sST2 in INS recurrence, the serum activity from recurrent and non-recurrent patients was tested on a mouse podocyte cell line before and after sST2 depletion, as well as the sST2 protein alone purified from these sera. As Saleem's team which had underlined the toxic activity of nephrotic plasma on the human podocyte cell line 17 , we also found significant morphological damages in podocytes incubated with sera from patients with recurrence, whereas cells exposed to sera from non-recurrent patients exhibited a normal morphology. However, despite the serum activity was exclusively restrained to sera from patients with recurrence, we found a low sensitivity of this assay, as several sera from recurrent patients were not able to induce these podocyte damages.
However, this could be due to the use of a mouse cell line with human sera, in contrary to Saleem who used human podocytes. Plasmas of recurrent patients, which presented an activity in vitro were then sST2-depleted and tested again on podocytes. Eluates containing purified sST2 proteins were not toxic, whereas the initial activity was present in sST2-depleted plasmas.
Finally, we tested the sST2 activity in vivo in Sprague-Dawley rats, using an adenoassociated virus containing the human sST2 gene sequence. Despite a high and durable expression of the sST2 protein, these animals did not develop proteinuria. However, to avoid a specie specific effect, we also injected the sST2 protein purified from healthy Lewis 1W or nephrotic Buffalo/Mna rats sera directly in the renal artery of Lewis 1W rats. Nevertheless, these animals did not develop proteinuria, whether the sST2 proteins came from Lewis 1W or sST2 from Buffalo/Mna rats, further suggesting that this protein alone is not capable to induce kidney damages.
Altogether, these results showed that although sST2 is strongly increased in recurrent INS patients after transplantation, this protein does not seem to be directly implicated in the development of nephrotic proteinuria. sST2 is known to be strongly upregulated in the sera of patients with various disorders associated with an abnormal Th2 response, including systemic lupus erythematosus, asthma and idiopathic pulmonary fibrosis [30] [31] [32] . In the case of INS recurrence, this augmentation might also not be the cause of the disease, but rather a reflection of an atypical Th2 activation. Table 1) . In this group, the proteinuria was related to different kidney graft lesions: allograft glomerulonephritis, recurrence of IgA nephritis or diabetes.
PATIENTS, MATERIALS AND METHODS
Patients
All of these patients gave informed consent to this study according to French legislative guidelines. Mouse podocyte cell culture: A previously described conditionally immortalized mouse podocyte cell line 16 was routinely maintained in RPMI-1640 medium (Sigma) containing 100 µg/mL streptomycin, 100 U/mL penicillin (Sigma) and 10% foetal calf serum (FCS, Abcys).
Quantification of human sST2 protein:
Podocytes were propagated on collagen I-coated plates (RD Systems) at 33°C in the presence of 10 U/mL of recombinant mouse -interferon (R&D Systems). Removal of -interferon and temperature switch to 37°C inactivated the SV40 T antigen and induced podocytes differentiation in 14 days.
In vitro effect of plasmas and sST2 on podocytes: After day 14 of podocytes differentiation, FCS of the medium was substituted with the same concentration (10%) of human plasma or serum from INS patients with or without recurrence. Plasmas which had a significant effect on podocytes were also tested after immunoadsorption of the sST2 proteins they contained, in parallel with this purified sST2. After 48h of incubation, cells were fixed in 4% paraformaldehyde for 20 minutes for immunofluorescence staining: after blocking 30 minutes with 10% NGS, podocytes were stained with TRITC-labeled phalloidin (Sigma) for Factin cytoskeleton visualization, with a monoclonal anti-vinculin antibody (Sigma) and the appropriate FITC-conjugated secondary antibody for the detection of the points of contact between the actin cytoskeleton and the extracellular matrix, and with DAPI for nuclear staining.
In vivo effect of sST2 in rat:
Animals: Overexpression of sST2 was induced through an AAV in healthy male SpragueDawley rats (Janvier, Le Genest Saint Isle, France), or by injection in healthy male Lewis 1W rats (Janvier, Le Genest Saint Isle, France) of the purified sST2 protein from other Lewis 1W rats or from nephrotic 6 months-old male Buffalo/Mna rats. The Buffalo/Mna strain maintained in our lab was originally kindly provided by Dr Saito (Central Experimental Institute, Nokawa, Kawasaki, Japan). At the time of experimentation, Buffalo/Mna rats displayed a proteinuria level between 0.4 and 0.8 g/mmol. The animal care was in accordance with our national institutional guidelines.
Construction of the AAV8-hST2 vector: AAV8 vector expressing human sST2 (hST2) driven by the ubiquitous RSV promoter was generated in the pZA-RSV-WPRE vector. For that, hST2 cDNA fragment (995 bp) was removed from pEFBOS-hST2 33 using BstXI, blunted and ligated downstream the RSV promoter and the chimeric intron into pZA-RSV-WPRE cut by
EcoRI and BamHI and blunt-ended to give the pZA-RSVhST2WPRE. AAV8 vector contains also the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) and SV40 polyadenylation signal flanked by inverted tandem repeats (ITRs). Recombinant AAV8 were manufactured as described elsewhere 34 and purified by cesium chloride density gradients followed by extensive dialysis against PBS.
Intra-arterial injection of purified rat sST2: Intra-arterial injection was chosen to optimize the exposure of the kidney to sST2 proteins. After measuring their preinjection proteinuria levels, animals were anesthetized with isofluorane, a right nephrectomy was performed, the aorta was clamped above and below the left renal artery and 600 µL of purified sST2 was slowly injected into the aorta left renal artery segment. Total time of ischemia was about 10 minutes.
After recovering, rats were placed in metabolic cages in order to collect their urine 24 h after the injection, and to measure diuresis. Over-all, two groups of 5 rats received purified sST2
from Lewis 1W and Buffalo/Mna. Control rats were injected with the same volume of an isotonic saline solution with the same procedure.
Proteinuria measurements: Rats were placed in metabolic cages for 24 h with free access to water but without food pellets which could fall into the urine collector and contaminate the samples. The total urinary protein concentration (g/L) was measured by a colorimetric method using a Hitachi autoanalyser (Boehringer). The urinary creatinine (mmol/L) was measured by the Jaffé method. Proteinuria was expressed according to this formula:
Proteinuria (g/mmol) = urinary proteins (g/L) / urinary creatinine (mmol/L). It was considered as abnormal when the value was above 0.2 g/mmol.
Statistical analyses:
The nonparametric Wilcoxon rank-sum test was used to compare sST2 levels between each cohort of patients. Receiver-Operating-Characteristic (ROC) curve analysis was performed with R software (http://www.r-project.org/) to determine the cut-off points of sST2 concentration in the serum that yielded the highest combined sensitivity and specificity in diagnosis of INS recurrence (see Figure 2 legend for explanations).
For comparison of rats' proteinuria levels before and at different points after injection of the AAV8-hST2 or purified sST2 protein, the Friedman test and a Dunn's multiple comparison test were used.
For each statistical test, P values under 0.05 were considered to be significant. Proteinuria (g/mmol)
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